NeuroOne Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced that its independent directors approved an equity award under the company's 2021 Inducement Plan as a material inducement for an individual to join the company. The grant, effective June 24, 2026, involves an option to purchase 10,000 shares of common stock at an exercise price of $3.27 per share, the closing price on the grant date. The award complies with Nasdaq Listing Rule 5635(c)(4), which requires public disclosure of such inducement grants not made under a stockholder-approved plan.

The option has a ten-year term and vests over four years, with 25% vesting on the first anniversary and the remainder in equal quarterly installments, contingent upon continued employment. The new hire, who was not previously an employee or director, will be subject to acceleration or forfeiture provisions as outlined in the option agreement. This move underscores NeuroOne's commitment to attracting key talent by offering equity incentives.

NeuroOne, based in Eden Prairie, Minnesota, is a medical technology company focused on improving surgical care for neurological disorders. The company markets a minimally invasive electrode technology platform with four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System (for brain), and OneRF Trigeminal Nerve Ablation System. These products aim to reduce hospitalizations, lower costs, and improve patient outcomes. Additionally, NeuroOne is researching drug delivery, basivertebral nerve ablation, and spinal cord stimulation. More information is available at nmtc1.com.

The inducement grant is a strategic move to incentivize new employees without needing stockholder approval, reflecting the company's need to secure specialized expertise in a competitive industry. By offering equity that vests over time, NeuroOne aligns the new hire's interests with long-term shareholder value. The announcement also provides transparency to investors about compensation practices that could impact dilution and employee retention.

The significance of this announcement lies in its implications for corporate governance and talent acquisition. Nasdaq's Rule 5635(c)(4) ensures that investors are informed when companies issue equity as a hiring inducement outside of standard plans, allowing them to assess potential dilution. For NeuroOne, this grant signals confidence in the new employee's contribution to advancing its product pipeline and clinical goals. The company's focus on neurological disorders and innovative electrode technology positions it to address unmet medical needs, making talent retention critical to its growth.

Investors and industry observers will monitor how such inducements affect NeuroOne's financials and operational milestones. The grant's vesting schedule ties the employee's rewards to sustained performance, potentially driving progress in the company's R&D programs. As NeuroOne continues to develop its offerings, including drug delivery and spinal cord stimulation, attracting skilled personnel remains essential. This inducement grant exemplifies a common practice among growth-stage medical technology firms to secure key hires while adhering to regulatory requirements.